Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues (Q28253419)

14

object named as

S Bahn

0 references

author name string

J T-J Huang

1

0 references

L Wang

2

0 references

S Prabakaran

3

0 references

M Wengenroth

4

0 references

H E Lockstone

5

0 references

D Koethe

6

0 references

C W Gerth

7

0 references

S Gross

8

0 references

D Schreiber

9

0 references

K Lilley

10

0 references

D Oxley

12

0 references

F M Leweke

Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress

13

0 references

language of work or name

English

0 references

publication date

December 2008

0 references

published in

Molecular Psychiatry

0 references

volume

13

0 references

issue

12

0 references

page(s)

1118-28

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4002108

Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4002108

Gene expression analysis in schizophrenia: reproducible up-regulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22.

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4002108

Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4002108

The molecular genetics of schizophrenia: new findings promise new insights

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

Abnormalities in glucose regulation associated with mental illness and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

The role of thyroid hormones in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

Protein profiling of human postmortem brain using 2-dimensional fluorescence difference gel electrophoresis (2-D DIGE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

Determinants of plasma HDL concentrations and reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

Differences in neuroanatomical sites of apoD elevation discriminate between schizophrenia and bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

Altered levels of acute phase proteins in the plasma of patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

Cholesterol and apolipoprotein E in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

Molecular pathways to neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

Crosstalk between nitric oxide and zinc pathways to neuronal cell death involving mitochondrial dysfunction and p38-activated K+ channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

The schizophrenia-rheumatoid arthritis connection: infectious, immune, or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

Association of plasma apolipoproteins D with RBC membrane arachidonic acid levels in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

7 January 2021

Muscle biopsy, macro EMG, and clinical characteristics in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

7 January 2021

The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

7 January 2021

Metabolic syndrome in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

7 January 2021

The hypothalamic-pituitary-thyroid axis in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002108

7 January 2021